Harvard scientists have merged stem cell and “organ-on-a-chip” technologies to grow, for the first time, functioning human heart tissue carrying an inherited cardiovascular disease.
The research appears to be a big step forward for personalized medicine, because it is working proof that a chunk of tissue containing a patient’s specific genetic disorder can be replicated in the laboratory.
The work, published in the journal Nature Medicine, is the result of a collaborative effort bringing together scientists from the Harvard Stem Cell Institute (HSCI), the Wyss Institute for Biologically Inspired Engineering,Boston Children’s Hospital, the Harvard School of Engineering and Applied Sciences (SEAS), and Harvard Medical School (HMS). It combines the “organs-on-chips” expertise of Kevin Kit Parker and stem cell and clinical insights byWilliam Pu.
Using their interdisciplinary approach, the investigators modeled the cardiovascular disease Barth syndrome, a rare X-linked cardiac disorder caused by mutation of a single gene called Tafazzin, or TAZ. The disorder, which is currently untreatable, primarily appears in boys, and is associated with a number of symptoms affecting heart and skeletal muscle function.
The researchers took skin cells from two Barth syndrome patients, and manipulated the cells to become stem cells that carried the patients’ TAZ mutations. Instead of using the stem cells to generate single heart cells in a dish, the cells were grown on chips lined with human extracellular matrix proteins that mimicked their natural environment, tricking the cells into joining together as they would if they were forming a diseased human heart. The engineered diseased tissue contracted very weakly, as would the heart muscle of a Barth syndrome patient.
The investigators then used genome editing, a technique pioneered by Harvard collaborator George Church, to mutate TAZ in normal cells, confirming that this mutation is sufficient to cause weak contraction in the engineered tissue. On the other hand, delivering the TAZ gene product to diseased tissue in the laboratory corrected the contractile defect, creating the first tissue-based model of correction of a genetic heart disease.
“You don’t really understand the meaning of a single cell’s genetic mutation until you build a huge chunk of organ and see how it functions or doesn’t function,” said Parker, who has spent more than a decade working on organs-on-chips technology. “In the case of the cells grown out of patients with Barth syndrome, we saw much weaker contractions and irregular tissue assembly. Being able to model the disease from a single cell all the way up to heart tissue, I think that’s a big advance.”
Furthermore, the scientists discovered the TAZ mutation works in such a way to disrupt the normal activity of mitochondria, often called the power plants of the cell for their role in making energy. However, the mutation didn’t seem to affect the overall energy supply of the cells. In what could be a newly identified function for mitochondria, the researchers describe a direct link between mitochondrial function and a heart cell’s ability to build itself in a way that allows it to contract.
“The TAZ mutation makes Barth syndrome cells produce an excess amount of reactive oxygen species, or ROS — a normal byproduct of cellular metabolism released by mitochondria — which had not been recognized as an important part of this disease,” said Pu, who cares for patients with the disorder.
“We showed that, at least in the laboratory, if you quench the excessive ROS production then you can restore contractile function,” added Pu, an affiliated faculty member at HSCI and a cardiologist at Boston Children’s. “Now, whether that can be achieved in an animal model or a patient is a different story, but if that could be done, it would suggest a new therapeutic angle.”
His team is now trying to translate this finding by doing ROS therapy and gene-replacement therapy in animal models of Barth syndrome to see what could potentially help human patients. At the same time, the scientists are using their human “heart disease-on-a-chip” as a testing platform for drugs that are under trial or already approved that might be useful to treat the disorder.
“We tried to thread multiple needles at once, and it certainly paid off,” Parker said. “I feel that the technology that we’ve got ‘arms’ industry and university-based researchers with the tools they need to go after this disease.”
Both Parker, the Tarr Family Professor of Bioengineering and Applied Physics at SEAS, and Pu, who first talked about collaborating while at a 2012 Stockholm conference, credit their partnership and scientific consilience for the success of this research. Parker, who is also a core faculty member of the Wyss Institute and a principal faculty member at HSCI, said that the “organs-on-chips” technology that has been a main effort of his lab only worked as fast and as well as it did because of the high quality of Pu’s patient-derived cardiac cells.
“When we first got those cells down on the chip, Megan [McCain], one of the joint first authors, texted me, ‘This is working,’” he recalled. “We thought we’d have a much harder fight.”
The Latest on: Organ-on-a-chip
via Google News
The Latest on: Organ-on-a-chip
- Draper Demonstrates Miniature Organ Models Can Play Key Role in COVID-19 Drug Developmenton July 1, 2020 at 12:12 am
Draper today announced the release of a new scientific article that describes how the company's technology can be used to test an in vitro human lung model to investigate responses following infection ...
- Draper Demonstrates Miniature Organ Models Can Play Key Role in COVID-19 Drug Developmenton June 22, 2020 at 5:00 pm
As many scientists are asking for models with stronger in vitro-in vivo correlation, the scientific community begins to turn more towards using organ-on-a-chip systems as a cost-effective and more ...
- Using Organs-on-chips technology to accelerate COVID-19 researchon June 15, 2020 at 9:21 pm
As part of this initiative, Emulate, Inc have donated blank Organ-Chips to the UK Organ-on-a-chip Technologies Network to support the development of therapeutics against the virus responsible for ...
- organ-on-a-chipon June 11, 2020 at 5:00 pm
SMi reports: Reyk Horland, Vice President, Business Development at TissUse GmbH to discuss “Applying Multi-Organ-on-a-Chip Technologies for Predictive TissUse GmbH to discuss multi-organ-on-a ...
- First 3-D Heart-on-a-Chip Has Integrated Sensingon June 10, 2020 at 5:00 pm
Harvard University researchers have made what they are touting as the first entirely 3D-printed organ-on-a-chip with integrated sensing. By using new printable inks for multi-material 3-D printing, ...
- Organ-on-a-chipon May 25, 2020 at 5:00 pm
Let's Talk Science. Let's Talk Medicine. The leading scientific social networking website and producer of educational virtual events and webinars.
- Cambridge-Based Emulate Plans to Jumpstart Organ-on-a-Chip Marketon May 21, 2020 at 5:00 pm
Like a cell culture, an organ-on-a-chip uses real human biology, in the form of thousands of human cells grown together in a fabricated microenvironment. Like an animal, it has functioning, ...
- Global Organ-on-a-Chip Market Report 2020: Lack of Scaling and Standardization Hampers Growthon May 14, 2020 at 7:20 am
DUBLIN, May 14, 2020 /PRNewswire/ -- The "Organ-on-a-Chip Global Market - Forecast To 2026" report has been added to ResearchAndMarkets.com's offering. Organ-on-a-Chip is gaining popularity as ...
- Global Organ-on-a-Chip Market Forecasts to 2026 by Product, Application, Material Type, End-user and Geography - ResearchAndMarkets.comon May 12, 2020 at 1:26 am
The "Organ-on-a-Chip Global Market - Forecast To 2026" report has been added to ResearchAndMarkets.com's offering. Organ-on-a-Chip is gaining popularity as they are rendered crucial for prognosis ...
- Europe Organ-on-a-chip MARKET 2020 UPDATED COVID-19 CRISIS FOR FUTURE DEVELOPMENT BY 2025on May 11, 2020 at 8:13 am
"The global Organ-on-a-chip market report offers information relating to the leading regions, competitive landscape, growth trends, and other crucial information about the growth status of the market.
via Bing News